Integration of PAT for the Development and Scale-up of a Hydrogenolysis Reaction

Tuesday, November 18, 2008: 3:15 PM
Room 106-B (Pennsylvania Convention Center)

Jale Müslehiddinoglu, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
Paul Lobben, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
Thomas Laporte, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
Lori Spangler, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
Daniel Fichana, Csm, Bristol-Myers Squibb Company, New Brunswick, NJ
Shih-Ying Chang, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
Donald Kientzler, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
Sushil Srivastava, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
John Venit, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
Robert Wethman, Analytical R&D, Bristol-Myers Squibb Company, New Brunswick, NJ
San Kiang, Process R&D, Bristol-Myers Squibb Company, New Brunswick, NJ

Although the Cbz deprotection reaction is a common organic reaction in the pharmaceutical industry, challenges were faced during the development and scale-up of this reaction at the API step due to the instability of the product in the reaction mixture. This led us to develop a control strategy as a part of quality by design approach. Consequently, a PAT (Process Analytical Technology) was used for continuous monitoring and control in order to ensure the quality of the product. This talk will describe the development of three in-process controls, using kinetics information from FTIR monitoring.
Extended Abstract: File Not Uploaded